Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595980 | 1.00 | TRPV1 (0.48) | TRPV1MAPTRXFP1RAB9ANPC1 | |
| SCHEMBL3579645 | 0.89 | TRPV1 (0.56) | TRPV1MAPTRXFP1RAB9ANPC1 | |
| SCHEMBL3579650 | 0.89 | TRPV1 (0.56) | TRPV1MAPTRXFP1RAB9ANPC1 | |
| SCHEMBL3589483 | 0.89 | TRPV1 (0.50) | TRPV1MAPTRXFP1RAB9ANPC1 | |
| SCHEMBL3589487 | 0.89 | TRPV1 (0.50) | TRPV1MAPTRXFP1RAB9ANPC1 | |
| SCHEMBL13544087 | 0.88 | TRPV1 (0.52) | TRPV1MAPTRXFP1RAB9ANPC1 | |
| SCHEMBL3597299 | 0.86 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL3597303 | 0.86 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL3592072 | 0.86 | TRPV1 (0.48) | TRPV1MAPTRXFP1RAB9ANPC1 | |
| SCHEMBL3592075 | 0.86 | TRPV1 (0.48) | TRPV1MAPTRXFP1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2007100758-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885MAPT 3251/4885RXFP1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.